ClinicalTrials.gg

Diabetes Mellitus, Type 2 clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 10,392 studies for Diabetes Mellitus, Type 2 across more than 10 countries. 1,415 are recruiting or about to start. 8,258 of them are mainly about Diabetes Mellitus, Type 2 (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Diabetes Mellitus, Lipoatrophic too: 10,396 studies, 1,414 open.

ClinicalTrials.gov finds 12,077 studies for Diabetes Mellitus, Type 2. How that becomes 10,382 here

This page counts the studies the registry files under Diabetes Mellitus, Type 2, and those it files under no condition that list Diabetes Mellitus, Type 2themselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 12,077Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −4Filed under a narrower condition, counted on its own pageDiabetes Mellitus, Lipoatrophic 4
  3. −264List Diabetes Mellitus, Type 2 as a condition, but the registry did not file them under itMost often written as “Type2 Diabetes” (56), “Type2 Diabetes Mellitus” (23), and “Type2Diabetes” (22). The registry filed them under other conditions only, most often Diabetes Mellitus (70) and Obesity (53).
  4. −1,504Match it another way907 name it in the title, 19 in a keyword, and 578 by a synonym or other text the search reads.
  5. 10,305Counted here and found by its search244 of them list Diabetes Mellitus, Type 2 in their own words; the registry filed them under no condition.
  6. +77
    Counted here, but its search does not find themThe first 20 of 77.
  7. 10,382The count on this page

Status

Completed
6,921
Status unknown
997
Recruiting
881
Terminated
494
Not yet recruiting
446
Active, not recruiting
332

Phase

Phase 3
1,470
Phase 4
1,221
Phase 1
1,138
Phase 2
1,046
Early Phase 1
70

Where

United States
3,305
China
909
Canada
756
Germany
756
United Kingdom
572
Denmark
477

Who develops what

Add Diabetes Mellitus, Type 2 to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 166 programs from 80 companies, 137 with this as their studies’ main aim; 39 with a live phase 3 study; 52 primary completions in the next 12 months. Compare Eli Lilly, Novo Nordisk and AstraZeneca here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
SemaglutideRecent, repeated
Evidence
  • NCT07866066 · Amgen · Phase 3 · live · comparator · “Semaglutide” · registered Oct 2026
  • NCT07801820 · Lepu Medical · Phase 2 · live · comparator · “Semaglutide Tablets” · registered Aug 2026
  • NCT07743983 · BrightGene Bio-Medical Technology Co., Ltd. · Phase 3 · live · comparator · “semaglutide” · registered Jul 2026
  • NCT07662213 · AstraZeneca · Phase 3 · live · comparator · “Semaglutide” · registered Jun 2026
  • NCT07653477 · The United Laboratories International Holdings Limited · Phase 3 · live · comparator · “Semaglutide Injection” · registered Jun 2026
Novo Nordisk A/S89% of its industry studiesUS: Novo Nordisk A/S (FDA 2019)EU: Novo Nordisk A/S (EMA 2018)1521 studies
MetforminRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07442006 · JW Pharmaceutical · Phase 4 · live · comparator · “Metformin” · registered Jan 2026
  • NCT07244003 · Huadong Medicine Co., Ltd. · Phase 4 · live · background · “Metformin” · registered Nov 2025
  • NCT07093476 · Celltrion · Phase 3 · live · background · “Metformin” · registered Jun 2025
  • NCT06972732 · Boryung Pharmaceutical Co., Ltd · Phase 4 · live · background · “Metformin” · registered May 2025
  • NCT06339086 · chengdu brilliant pharmaceutical co ltd · Phase 3 · live · background · “Metformin” · registered Mar 2024
AstraZeneca9% of its industry studies1212 studies
dapagliflozinRecent, repeated
Evidence
  • NCT07082114 · Huadong Medicine Co., Ltd. · Phase 3 · live · comparator · “Dapagliflozin (DAPA)” · registered Jul 2025
  • NCT06972732 · Boryung Pharmaceutical Co., Ltd · Phase 4 · live · comparator · “Dapagliflozin/Sitagliptin” · registered May 2025
  • NCT06589765 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “dapagliflozin tablet” · registered Sep 2024
  • NCT06415773 · Shenzhen HighTide Biopharmaceutical Ltd. · Phase 3 · comparator · “Dapagliflozin” · registered May 2024
  • NCT06192108 · Eli Lilly and Company · Phase 3 · comparator · “Dapagliflozin” · registered Dec 2023
AstraZeneca82% of its industry studiesUS: off-patent, 22 generics marketedEU: off-patent, 1 generic authorized88 studies
dulaglutideRecent, repeated
Evidence
  • NCT07156539 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Dulaglutide Injection” · registered Aug 2025
  • NCT07109700 · Huadong Medicine Co., Ltd. · Phase 2 · live · comparator · “Dulaglutide 1.5 MG” · registered Jul 2025
  • NCT06901648 · Hansoh Pharmaceutical Group Company Limited · Phase 2 · comparator · “Dulaglutide” · registered Feb 2025
  • NCT06257966 · Beijing Dongfang Biotech Co., Ltd. · Phase 3 · live · comparator · “Dulaglutide” · registered Feb 2024
  • NCT05680129 · Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3 · comparator · “Dulaglutide” · registered Dec 2022
Eli Lilly and Company96% of its industry studiesUS: Eli Lilly and Company (FDA 2014)EU: Eli Lilly and Company (EMA 2014)56 studies
insulin degludecRecent, repeated
Evidence
  • NCT07913061 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “insulin degludec” · registered Oct 2026
  • NCT07527078 · Gan & Lee Pharmaceuticals · Phase 3 · live · comparator · “Insulin Degludec Injection (Tresiba®)” · registered Apr 2026
  • NCT07215312 · Eli Lilly and Company · Phase 2 · live · comparator · “Degludec” · registered Oct 2025
  • NCT07018453 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Insulin Degludec” · registered Jun 2025
  • NCT06202079 · Gan & Lee Pharmaceuticals · Phase 2 · comparator · “Insulin Degludec” · registered Jan 2024
Novo Nordisk A/S93% of its industry studiesUS: Novo Nordisk A/S (FDA 2015)EU: Novo Nordisk A/S (EMA 2013)49 studies
TirzepatideRecent, repeated
Evidence
  • NCT07889648 · Hoffmann-La Roche · Phase 3 · live · comparator · “Tirzepatide” · registered Oct 2026
  • NCT07796477 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Tirzepatide Injection 15mg” · registered Aug 2026
  • NCT06534411 · Novo Nordisk A/S · Phase 3 · comparator · “Tirzepatide” · registered Jul 2024
  • NCT06221969 · Novo Nordisk A/S · Phase 3 · comparator · “Tirzepatide” · registered Jan 2024
Eli Lilly and Company96% of its industry studiesUS: Eli Lilly and Company (FDA 2022)EU: Eli Lilly and Company (EMA 2022)34 studies
Insulin GlargineRecent, repeated
Evidence
  • NCT06871761 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “insulin glargine” · registered Feb 2025
  • NCT06688123 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Insulin glargine” · registered Nov 2024
  • NCT06370715 · Eli Lilly and Company · Phase 4 · background · “Insulin Glargine” · registered Apr 2024
  • NCT06269107 · Novo Nordisk A/S · Phase 3 · comparator · “Insulin glargine” · registered Feb 2024
  • NCT05803421 · Eli Lilly and Company · Phase 3 · comparator · “Insulin Glargine” · registered Mar 2023
Sanofi65% of its industry studiesUS: Sanofi (FDA 2000) + 3 othersEU: Sanofi (EMA 2000) + 3 others38 studies
mazdutideRecent, repeated
Evidence
  • NCT07843862 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Mazdutide” · registered Sep 2026
  • NCT07417306 · Huadong Medicine Co., Ltd. · Phase 3 · live · comparator · “Mazdutide” · registered Feb 2026
Innovent Biologics, Inc.74% of its industry studies22 studies
Insulin AspartRecent, repeated
Evidence
  • NCT06558708 · Gan & Lee Pharmaceuticals · Phase 2 · live · background · “Insulin aspart” · registered Aug 2024
  • NCT05413369 · Sanofi · Phase 3 · comparator · “IDegAsp” · registered Jun 2022
  • NCT04974528 · Mannkind Corporation · Phase 3 · comparator · “Rapid-acting Insulin Analog” · registered Jun 2021
  • NCT03430856 · Biocon Limited · Phase 3 · comparator · “Insulin Aspart” · registered Nov 2017
  • NCT03211858 · Sanofi · Phase 3 · comparator · “NovoLog/NovoRapid” · registered Jul 2017
Novo Nordisk A/S88% of its industry studiesUS: Novo Nordisk A/S (FDA 2001) + 1 otherEU: Novo Nordisk A/S (EMA 1999) + 3 others22 studies
empagliflozinRecent, repeated
Evidence
  • NCT06083675 · Novo Nordisk A/S · Phase 3 · comparator · “Empagliflozin” · registered Oct 2023
  • NCT05444153 · Novo Nordisk A/S · Phase 3 · comparator · “Empagliflozin” · registered Jun 2022
  • NCT05232071 · Inventiva Pharma · Phase 2 · background · “Empagliflozin” · registered Jan 2022
  • NCT05028140 · EMS · Phase 3 · live · comparator · “EMPAGLIFLOZIN” · registered Aug 2021
  • NCT04970108 · EMS · Phase 3 · comparator · “Empagliflozin + telmisartan” · registered Jul 2021
Boehringer Ingelheim70% of its industry studiesEU: Boehringer Ingelheim (EMA 2014)23 studies
alogliptinRecent, repeated
Evidence
  • NCT07093476 · Celltrion · Phase 3 · live · background · “Alogliptin” · registered Jun 2025
  • NCT05782192 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Alogliptin” · registered Mar 2023
  • NCT03499704 · Celltrion · Phase 4 · comparator · “Alogliptin” · registered Apr 2018
Takeda92% of its industry studiesUS: Takeda (FDA 2013)EU: Takeda (EMA 2013)22 studies

51 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
QLG1091☆ Track1 live phase-3 study: NCT07487103Qilu Pharmaceutical Co., Ltd.
empagliflozinApproved: EU 2014☆ Track1 live phase-3 study: NCT07093476Celltrion
maridebart cafraglutide☆ Track4 live phase-3 studies: NCT07866066, NCT07684144, NCT06858878Amgen
ribupatide☆ Track1 live phase-3 study: NCT07060456Jiangsu HengRui Medicine Co., Ltd.
HDM1002☆ Track2 live phase-3 studies: NCT07193459, NCT07082114Huadong Medicine Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 166 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (52)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.LY3938577 · Eli Lilly and Company · Phase 2 main aim+ LY3938577 vs insulin degludecNCT07215312 A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin — primary endpoint: Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) · 100 enrolled
  • Dec 2026 est.SHR-3167 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aimNCT07472725 A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents — primary endpoint: The percentage of participants who experienced at least one hypoglycemic event. · 102 enrolled
  • Dec 2026 est.QLG1091 · Qilu Pharmaceutical Co., Ltd. · Phase 3 main aim+ QLG1091 vs SemaglutideNCT07487103 Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes — primary endpoint: Change in HbA1c · 478 enrolled

49 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diabetes Mellitus, Type 2 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 59 open · SGLT2 inhibitors 45 open · DPP-4 inhibitors 8 open · Angiotensin receptor blockers (ARBs) 5 open · Mineralocorticoid receptor antagonists (MRAs) 5 open

Coming up

554studies finish main data collection within a year33 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger. 52 (6%) take children under 18. 28 (3%) are for women only and 5 (1%) for men only; 204 (23%) take healthy volunteers.

Recruiting studies that take each age, of 881
AgeWomenMen
1029 (3%)28 (3%)
18573 (65%)555 (63%)
30703 (80%)684 (78%)
40767 (87%)747 (85%)
50793 (90%)776 (88%)
65778 (88%)762 (86%)
75611 (69%)598 (68%)
85417 (47%)403 (46%)

Across all 10,392 studies, recruiting or not: 49% stop at 75 or younger and 23% at 65; 6% take children; 2% are for women only and 4% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetes Mellitus, Type 2 studies take

Of 525 phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 20 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 16 mo2–14 · 515 studies5 mo2–11 · 453 studies24 mo11–41 · 62 studies
Phase 1/228 mo22–71 · 41 studies——
Phase 215 mo11–27 · 293 studies13 mo9–18 · 194 studies34 mo16–50 · 99 studies
Phase 2/322 mo13–31 · 32 studies—21 mo11–30 · 26 studies
Phase 320 mo14–30 · 525 studies19 mo14–26 · 438 studies31 mo16–47 · 87 studies
Phase 424 mo13–42 · 452 studies19 mo12–28 · 132 studies31 mo14–49 · 320 studies
Interventional, no phase21 mo10–39 · 2,247 studies16 mo6–29 · 177 studies21 mo10–40 · 2,070 studies
Observational32 mo17–63 · 604 studies25 mo16–44 · 170 studies35 mo17–96 · 434 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Started recruiting23

Show 18 more

Newly registered83

Show 45 more

and 33 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 10,392. Browse all 10,392 → or search them.